David M. Mott

Insider Reports History

Location
Baltimore, MD
Signature
/s/ Elizabeth Grammer, Attorney-in-Fact for David Mott
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by David M. Mott:

Form 4 holding Director

IMARA Inc.

Security class
Common Stock
Shares / value
229,224
Estimated value
$3,469,305
Report date
02 Jun 2022
Price
$15.14
Ownership
Direct
Form 4 holding Director

NOVAVAX INC

Security class
Stock Option (Right to Buy)
Shares / value
28,326
Estimated value
$181,852
Report date
20 Jun 2025
Price
$6.42
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

NOVAVAX INC

Security class
Restricted Stock Units
Shares / value
18,884
Estimated value
$144,838
Report date
20 Jun 2025
Price
$13.90
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ARDELYX, INC.

Security class
Stock Option (Right to Buy)
Shares / value
54,059
Estimated value
$0
Report date
18 Jun 2025
Price
$2.32
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
1,583,214
Estimated value
Report date
01 Jul 2024
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

IMARA Inc.

Security class
Stock Options (Right to Buy)
Shares / value
8,500
Estimated value
Report date
02 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Epizyme, Inc.

Security class
Common Stock, par value $0.0001
Shares / value
0
Estimated value
Report date
12 Aug 2022
Price
$1.41
Ownership
Direct
Form 4 holding Director

Epizyme, Inc.

Security class
Common Stock, par value $0.0001
Shares / value
0
Estimated value
Report date
12 Aug 2022
Price
$1.41
Ownership
Indirect

Insider Reports Filed by David M. Mott

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .